Item 1.01. Entry into a Material Definitive Agreement.
On January 10, 2021, Applied DNA Sciences, Inc. (the “Company,”
“we” or “us”) entered into a placement agency agreement (the “Placement Agreement”)
with Roth Capital Partners, LLC (the “Placement Agent”) pursuant to which the Placement Agent agreed to serve
as the exclusive placement agent, on a “reasonable best efforts” basis, in connection with the registered direct public
offering of 1,810,000 shares (the “Shares”) of our common stock, par value $0.001 (the “Common Stock”).
Each Share will be sold at a purchase price of $8.30 per share of Common Stock (the “Public Offering Price”)
through the Placement Agent (the “Registered Direct Offering”). Also on January 10, 2021, to effect the Registered
Direct Offering, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with
certain institutional investors named in the signature pages thereto (the “Purchasers”) pursuant to which we
agreed to issue and sell the Shares directly to the Purchasers at the Public Offering Price.
We expect to receive aggregate proceeds, after deducting Placement
Agent fees related to the Registered Direct Offering, in the amount of approximately $13,971,390. We intend to use the net
proceeds from this offering for general corporate purposes, including working capital, for research and development, and to advance
the adoption of our LinearDNA™ manufacturing platform.
The closing of the
Registered Direct Offering is expected to take place on January 13, 2021, subject to customary closing conditions. The Shares are
being offered and sold to the public pursuant to our shelf registration statement on Form S-3 (File No. 333-238557) initially filed
with the Securities and Exchange Commission (the “Commission”) on May 21, 2020 and declared effective on June
1, 2020. A prospectus supplement relating to the Registered Direct Offering will be filed with the Commission on or about January
12, 2021.
The Securities Purchase Agreement contains customary representations,
warranties and agreements by us and customary conditions to closing. Under the Securities Purchase Agreement, and subject to certain
exceptions, we have agreed not to (i) enter into any agreement to issue or announce the issuance or proposed issuance of any Common
Stock or Common Stock equivalents, or (ii) file any registration statement or amendment or supplement thereto, for a period of
90 days following the closing of the offering.
In connection with
this offering, we and each of our executive officers and directors have agreed, subject to certain exceptions set forth in the
lock-up agreements, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly,
any shares of our Common Stock, or any securities convertible into or exercisable or exchangeable for shares of our Common Stock,
or publicly disclose the intention to make any offer, sale, pledge or disposition, for 90 days from the date of the prospectus
supplement relating to this offering.
Pursuant to the Placement
Agreement, we have agreed to pay the Placement Agent a cash placement fee equal to 7.0% of the aggregate gross proceeds raised
in this offering from sales arranged for by the Placement Agent. Subject to certain conditions, we also have agreed to reimburse
all travel and other out-of-pocket expenses of the Placement Agent in connection with this offering, including but not limited
to legal fees, up to a maximum of $50,000. The Placement Agreement contains customary representations, warranties and agreements
by us and customary conditions to closing. We have agreed to indemnify the Placement Agent against certain liabilities, including
liabilities under the Securities Act of 1933, as amended (the “Securities Act”), and liabilities arising from
breaches of representations and warranties contained in the Placement Agreement, or to contribute to payments that the Placement
Agent may be required to make in respect of those liabilities.
The
foregoing descriptions of the Placement Agreement and the Securities Purchase Agreement do not purport to be complete and
are qualified in their entirety by reference to the full text of the Form of Placement Agreement and the Form of Securities Purchase
Agreement, which are attached to this Current Report on Form 8-K as Exhibits 10.1 and 10.2, respectively, and incorporated herein
by reference in their entirety.
We note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
in the prospectus supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement,
including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to
be a representation, warranty or covenant to or in favor of any stockholder or potential stockholder of the Company other than
the parties thereto. In addition, the assertions embodied in any representations, warranties and covenants contained in such agreements
may be subject to qualifications with respect to knowledge and materiality different from those applicable to security holders
generally. Moreover, such representations, warranties or covenants were accurate only as of the date when made, except where expressly
stated otherwise. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing
the current state of our affairs at any time.
Forward-Looking Statements
This Current Report
on Form 8-K contains statements which may be “forward-looking” in nature within the meaning of Section 27A of the Securities
Act, Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and the Private Securities
Litigation Reform Act of 1995. Forward-looking statements describe the Company’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of risks and uncertainties, including market conditions, the completion
of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds
from the offering, many of which are beyond the control of the Company. These statements are based on current expectations, estimates
and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including
those risks factors detailed from time to time in the Company’s reports and filings with the Commission, including its Annual
Report on Form 10-K filed on December 17, 2020, and other reports it files with the Commission, which are available at www.sec.gov.
The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
The prospectus supplement
relating to the Registered Direct Offering will be filed with the Commission and will be available on the Commission’s web
site at http://www.sec.gov.
This report does not
constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state or jurisdiction
in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of
any state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part
of the effective registration statement.